Aliases & Classifications for Aging

MalaCards integrated aliases for Aging:

Name: Aging 56 74

External Ids:

OMIM 56 502000

Summaries for Aging

OMIM : 56 Progressive damage to mitochondrial DNA (mtDNA) during life is thought to contribute to aging processes. This notion is supported by the observation of an aging-related accumulation in human mtDNA of oxidative and alkylation derivatives of nucleotides, of small deletions and insertions, and of large deletions, although their low frequency raises questions about their functional significance (Michikawa et al., 1999). (502000)

MalaCards based summary : Aging is related to premature aging and atypical werner syndrome. An important gene associated with Aging is BCYRN1 (Brain Cytoplasmic RNA 1), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Cellular Senescence (REACTOME). The drugs Darunavir and Oxycodone have been mentioned in the context of this disorder. Affiliated tissues include brain, skin and heart, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Senescence (/s?'n?s?ns/) or biological aging is the gradual deterioration of functional characteristics.... more...

Related Diseases for Aging

Diseases related to Aging via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 5790)
# Related Disease Score Top Affiliating Genes
1 premature aging 33.5 WRN TP63 SOD2 PDGFRB LMNA
2 atypical werner syndrome 32.6 WRN LMNA
3 hutchinson-gilford progeria syndrome 32.4 WRN TP53 SOD2 SIRT1 LMNA
4 friedreich ataxia 32.2 TP53 SOD2 SOD1 PPARG
5 senile cataract 32.2 WRN SOD1 LMNA
6 cataract 32.1 WRN TP53 SOD2 SOD1 SIRT1 LMNA
7 huntington disease 32.0 TP53 SOD2 SOD1 SNCA PPARG AKT1
8 skin carcinoma 31.8 TP53 MAPK1 JUN AKT1
9 vascular disease 31.8 TP53 SOD1 SERPINE1 PPARG NAMPT MAPK1
10 medulloblastoma 31.7 WRN TP53 SIRT1 PDGFRB MAPK1 JUN
11 kaposi sarcoma 31.7 TP53 MAPK1 JUN AKT1
12 spinal muscular atrophy 31.6 TP53 SOD1 SNCA LMNA
13 neuroblastoma 31.6 TP53 SOD2 SOD1 SNCA PDGFRB MAPK1
14 fibrosarcoma 31.5 TP53 SOD2 SERPINE1 MAPK1 JUN
15 non-alcoholic fatty liver disease 31.5 SIRT1 SERPINE1 PPARG NAMPT JUN AKT1
16 leukemia, acute myeloid 31.5 TP53 SNCA SIRT1 PDGFRB MAPK1 JUN
17 primary lateral sclerosis, adult, 1 31.4 SOD1 SNCA
18 microvascular complications of diabetes 5 31.3 SOD2 SOD1 SERPINE1 AKT1
19 hypertension, essential 31.3 TP53 SOD2 SIRT1 SERPINE1 PPARG NAMPT
20 dilated cardiomyopathy 31.2 TP53 SOD2 SOD1 SERPINE1 PPARG MAPK1
21 osteoporosis 31.2 WRN TP53 SOD2 SIRT1 SERPINE1 PPARG
22 wilms tumor 1 30.8 TP63 TP53 KCNQ1DN AKT1
23 retinitis pigmentosa 30.8 TP53 SOD2 SOD1 SNCA SIRT1 LMNA
24 alzheimer disease 30.8 TP53 SOD2 SOD1 SNCA SIRT1 PPARG
25 diabetes mellitus, noninsulin-dependent 30.6 WRN TP53 SOD1 SIRT3 SIRT1 SERPINE1
26 sarcoma 30.6 TP53 PDGFRB MAPK1 JUN AKT1
27 skin atrophy 30.6 WRN LMNA KL
28 hyperglycemia 30.6 SOD2 SOD1 SERPINE1 PPARG NAMPT JUN
29 cardiovascular system disease 30.4 SOD1 SERPINE1 PPARG NAMPT AKT1
30 cervical cancer 30.4 TP63 TP53 MAPK1 JUN BCYRN1 AKT1
31 tuberous sclerosis 30.4 TP53 PDGFRB MAPK1 AKT1
32 glioblastoma multiforme 30.4 TP53 PPARG PDGFRB MAPK1 JUN AKT1
33 overnutrition 30.3 SIRT1 SERPINE1 PPARG NAMPT AKT1
34 gastric adenocarcinoma 30.3 TP53 PDGFRB MAPK1 JUN AKT1
35 thyroid gland follicular carcinoma 30.3 TP53 PPARG AKT1
36 breast adenocarcinoma 30.2 TP53 SOD2 SERPINE1 MAPK1 AKT1
37 pneumoconiosis 30.2 SOD1 SERPINE1 JUN
38 prion disease 30.1 SOD2 SOD1 SNCA
39 esophageal cancer 30.1 TP63 TP53 SIRT1 PPARG MAPK1 JUN
40 estrogen-receptor positive breast cancer 30.0 TP53 JUN AKT1
41 diabetes mellitus 29.9 WRN SOD2 SOD1 SIRT1 SERPINE1 PPARG
42 body mass index quantitative trait locus 11 29.9 TP53 SOD2 SIRT3 SIRT1 SERPINE1 PPARG
43 skin papilloma 29.9 TP53 JUN AKT1
44 pancreatic adenocarcinoma 29.9 TP53 PDGFRB MAPK1 JUN AKT1
45 adult t-cell leukemia 29.8 TP53 JUN AKT1
46 muscular disease 29.7 TP53 SOD1 SIRT1 LMNA AKT1
47 glucose metabolism disease 29.7 SIRT1 SERPINE1 PPARG AKT1
48 toxic encephalopathy 29.6 SOD1 SNCA AKT1
49 hair disease 29.6 TP53 LMNA AKT1
50 marek disease 29.5 TP53 JUN

Graphical network of the top 20 diseases related to Aging:



Diseases related to Aging

Symptoms & Phenotypes for Aging

Clinical features from OMIM:

502000

GenomeRNAi Phenotypes related to Aging according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.63 MAPK1
2 Decreased viability GR00221-A-1 10.63 AKT1 MAPK1 PDGFRB PPARG
3 Decreased viability GR00221-A-2 10.63 AKT1 PPARG SOD1 JUN
4 Decreased viability GR00221-A-3 10.63 AKT1 MAPK1 PDGFRB PPARG SOD1 JUN
5 Decreased viability GR00221-A-4 10.63 AKT1 MAPK1 PDGFRB PPARG SOD1
6 Decreased viability GR00231-A 10.63 MAPK1
7 Decreased viability GR00342-S-1 10.63 MAPK1 PDGFRB
8 Decreased viability GR00342-S-2 10.63 MAPK1
9 Decreased viability GR00342-S-3 10.63 MAPK1
10 Decreased viability GR00402-S-2 10.63 AKT1 MAPK1 PDGFRB PPARG SOD1 JUN
11 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 AKT1 JUN SIRT1 SNCA SOD1 TP53
12 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 AKT1 JUN MAPK1 SIRT1 SNCA SOD1
13 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 JUN SIRT1 SOD1 TP53 TP63 WRN

MGI Mouse Phenotypes related to Aging:

45 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.58 AKT1 JUN KL LMNA MAPK1 NAMPT
2 growth/size/body region MP:0005378 10.54 AKT1 JUN KL LMNA MAPK1 NAMPT
3 cellular MP:0005384 10.52 AKT1 JUN KL LMNA MAPK1 PDGFRB
4 homeostasis/metabolism MP:0005376 10.51 AKT1 JUN KL LMNA MAPK1 NAMPT
5 behavior/neurological MP:0005386 10.5 AKT1 JUN KL LMNA MAPK1 PDGFRB
6 immune system MP:0005387 10.48 AKT1 JUN KL LMNA MAPK1 NAMPT
7 integument MP:0010771 10.47 AKT1 JUN KL LMNA MAPK1 NAMPT
8 mortality/aging MP:0010768 10.45 AKT1 JUN KL LMNA MAPK1 NAMPT
9 endocrine/exocrine gland MP:0005379 10.44 AKT1 JUN KL LMNA MAPK1 NAMPT
10 adipose tissue MP:0005375 10.41 AKT1 KL LMNA PDGFRB PPARG RGN
11 hematopoietic system MP:0005397 10.41 AKT1 JUN KL LMNA MAPK1 NAMPT
12 liver/biliary system MP:0005370 10.32 AKT1 JUN KL LMNA MAPK1 PPARG
13 nervous system MP:0003631 10.28 AKT1 JUN KL LMNA MAPK1 NAMPT
14 digestive/alimentary MP:0005381 10.26 KL LMNA MAPK1 PDGFRB SIRT1 SNCA
15 embryo MP:0005380 10.25 AKT1 JUN MAPK1 NAMPT PDGFRB PPARG
16 craniofacial MP:0005382 10.21 KL LMNA MAPK1 PDGFRB SIRT1 TP53
17 hearing/vestibular/ear MP:0005377 10.18 KL LMNA MAPK1 PPARG RGN SOD1
18 muscle MP:0005369 10.18 AKT1 KL LMNA MAPK1 PDGFRB PPARG
19 neoplasm MP:0002006 10.16 AKT1 MAPK1 PPARG SERPINE1 SIRT1 SOD1
20 limbs/digits/tail MP:0005371 10.13 KL LMNA PDGFRB RGN SIRT1 TP53
21 normal MP:0002873 10.07 AKT1 JUN LMNA PDGFRB PPARG SIRT1
22 reproductive system MP:0005389 10.07 AKT1 KL LMNA MAPK1 PDGFRB PPARG
23 renal/urinary system MP:0005367 10.02 KL LMNA PDGFRB PPARG SERPINE1 SIRT1
24 no phenotypic analysis MP:0003012 9.95 JUN PPARG SIRT1 SIRT3 SNCA TP53
25 respiratory system MP:0005388 9.85 AKT1 JUN KL LMNA MAPK1 RGN
26 skeleton MP:0005390 9.83 AKT1 JUN KL LMNA MAPK1 PDGFRB
27 vision/eye MP:0005391 9.44 JUN KL LMNA MAPK1 PDGFRB PPARG

Drugs & Therapeutics for Aging

Drugs for Aging (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 924)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
2
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
3
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
4
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
5
Remifentanil Approved Phase 4 132875-61-7 60815
6
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
7
Esmolol Approved Phase 4 81147-92-4, 103598-03-4 59768
8
Cisatracurium Approved Phase 4 96946-41-7
9
Pantoprazole Approved Phase 4 102625-70-7 4679
10
Cobicistat Approved Phase 4 1004316-88-4
11
Rilpivirine Approved Phase 4 500287-72-9
12
Ticlopidine Approved Phase 4 55142-85-3 5472
13
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
14
Ramipril Approved Phase 4 87333-19-5 5362129
15
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
16
Polyestradiol phosphate Approved Phase 4 28014-46-2
17
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
18
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
19
Phylloquinone Approved, Investigational Phase 4 84-80-0
20
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
21
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
22
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
23
Enalaprilat Approved Phase 4 76420-72-9 6917719
24
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
25
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
26
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
27
Menthol Approved Phase 4 2216-51-5 16666
28
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
29
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
30
Rivaroxaban Approved Phase 4 366789-02-8
31
Hydralazine Approved Phase 4 86-54-4 3637
32
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
33
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
34
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
35
Cimetidine Approved, Investigational Phase 4 51481-61-9 2756
36
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
37
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
38
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
39
Indapamide Approved Phase 4 26807-65-8 3702
40
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
41
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
42
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
43
Doxazosin Approved Phase 4 74191-85-8 3157
44
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
45
Spirapril Approved Phase 4 83647-97-6 5311447
46
Atenolol Approved Phase 4 29122-68-7 2249
47
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
48
Simvastatin Approved Phase 4 79902-63-9 54454
49
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
50
Desflurane Approved Phase 4 57041-67-5 42113

Interventional clinical trials:

(show top 50) (show all 3654)
# Name Status NCT ID Phase Drugs
1 Different Doses Rosuvastatin Effect on Telomere-telomerase System in Acute Coronary Syndrome Patients After Percutaneous Coronary INtervention: RETAIN Study Unknown status NCT02299245 Phase 4 rosuvastatin
2 Medication Induced Blood Pressure Reduction; Assessment of Cerebral Perfusion and Cognition in Hypertensive Elderly Unknown status NCT00966199 Phase 4 anti-hypertensive medication
3 Outcome Comparison Between PFNA and InterTAN in Intertrochanteric Fractures Unknown status NCT01797237 Phase 4
4 Cognitive, Behavioral and Aging Effects of Pain Medication in Alcohol Users Unknown status NCT02945293 Phase 4
5 The Effect of Dexmedetomidine on Postoperative Recovery in Elderly Patients With Femoral Neck Fracture Undergoing Hip Hemi-arthroplasty Unknown status NCT01934049 Phase 4 Total Intravenous Anesthesia and Peripheral nerve blocks
6 Can Methylphenidate (Ritalin) Improve Memory and Attention in Mild Cognitive Impairment? A Combined Behaviour-EEG Study Unknown status NCT02326038 Phase 4 Methylphenidate
7 Phase 4 Study of Long Term Postoperative Cognitive Dysfunction After Laparoscopic Cholecystectomy in the Elderly Patients Unknown status NCT02301676 Phase 4 Sevoflurane;propofol
8 An Open-Label Pilot Study to Compare the Efficacy of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids Unknown status NCT01583478 Phase 4
9 Treatment of Intertrochanteric Fracture With New Type of Intramedullary Nail Unknown status NCT01437176 Phase 4
10 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
11 Group Mindfulness-Based Cognitive Therapy for the Treatment of Late-Life Depression and Anxiety Symptoms in Primary Care: A Randomized Controlled Trial Unknown status NCT02777905 Phase 4
12 Frailty and Cognitive Function Assessment of TAVI Patients (The Hungarian Frailty Score) - Observational, Prospective, Singe Center Study Unknown status NCT02650388 Phase 4
13 The Efficacy and Optimal Dose of Sufentanil in Patient Controlled Analgesia After Moderate Surgery Unknown status NCT02503826 Phase 4 Sufentanil;Sufentanil;Sufentanil;Midazolam;propofol;cisatracurium
14 Multi-Centre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury Unknown status NCT00725790 Phase 4 Vardenafil;Placebo
15 CHADSS: Chagas Disease Scan Study Unknown status NCT01650792 Phase 4 Aspirin
16 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
17 Effects of a Chronical Treatment With Benfotiamine in People With Type 2 Diabetes Mellitus on Pre- and Postprandial Endothelial Function, as Well as on the Function of the Autonomic Nervous System Unknown status NCT00446810 Phase 4 Benfotiamine;Placebo
18 The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation on the Number of Oocytes Obtained During IVF in Poor Ovarian Responders Unknown status NCT02357472 Phase 4 dehydroepiandrosterone
19 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES" Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
20 A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT) Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
21 Effect of Controlled Hypotension on Cerebral Oxygen Saturation in Patients Undergoing Functional Endoscopic Sinus Surgery: a Prospective Randomized Single Blind Clinical Trial Unknown status NCT02967029 Phase 4 Esmolol Hydrochloride;Remifentanil Hydrochloride
22 The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound Unknown status NCT00813631 Phase 4
23 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLightTM Laser Photoselective Vaporization of the Prostate (PVP): A Randomized Double Blind Sexual and Urodynamic Assessment Unknown status NCT02749604 Phase 4
24 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
25 Endovascular Treatment Versus Optimal Medical Treatment of Atherosclerotic Renal Artery for Preserving Renal Function of the Ischemic Kidney. Unknown status NCT01208714 Phase 4 Optimal medical therapy
26 Discovery of Effects of Retinol on Human Skin Aging in Individuals of East Asian Descent Completed NCT02906566 Phase 4 Retinol;Placebo
27 Metformin in Longevity Study (MILES). Completed NCT02432287 Phase 4 Metformin;Placebo
28 Physiologic Effects of PRMS & Testosterone in the Debilitated Elderly Completed NCT00018356 Phase 4 testosterone
29 Genomic Outcomes of Metformin Completed NCT02986659 Phase 4 Metformin;Placebo
30 Multi-parameter Immune Profile Associated With the Humoral Response to Influenza Vaccine, Vaxigrip® in Healthy and Frail Elderly Subjects Aged 65-90 Years in Singapore Completed NCT03266237 Phase 4 Vaxigrip®
31 hCG Priming Prior to COH in Poor Responder IVF Patients Completed NCT00870025 Phase 4
32 Aging White Matter Changes, Executive Dysfunction and Depression Completed NCT00918684 Phase 4 Escitalopram
33 Canadian Study of the Use of Injectable POLY-L-LACTIC Acid (Sculptra Therapy) in Aesthetic Medicine Completed NCT00447551 Phase 4 Poly-L-Lactic Acid
34 A Comparative Randomized Double-Blinded Study of the Effect of Dysport and Botox on Forehead Wrinkles and EMG Activity Completed NCT00434863 Phase 4 botulinum toxin type A
35 The Effects of Pectin on Aging-related Changes in Intestinal Barrier Function, Immune Function and Microbial Composition Completed NCT02376270 Phase 4
36 Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines Completed NCT00856414 Phase 4
37 Volume Restoration of the Aging Midface With Sculptra Aesthetic Completed NCT01307865 Phase 4 injectable poly-L-lactic acid
38 A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Center Study on the Effects of a Proprietary Blend of Herbal Extract Supplement on Cellular Detoxification, Inflammation, and Cumulative Cognitive Index as Well as Gene Expression in Middle-Aged Adult Women. Completed NCT01598272 Phase 4
39 Immunogenicity of Pneumococcal Vaccination and Revaccination in Older Adults Completed NCT00239694 Phase 4
40 Clinical Evaluation of Day and Night Skin Care Creams Supplemented With MediCell Technology (MCT)'s Composition of Defensins and Supportive Molecules Completed NCT02765763 Phase 4 2-Minute Reveal Masque;24/7 Barrier Repair Cream;8-in-1 BioSerum;Null Formula 2-Minute Reveal Masque;Null Formula 24/7 Barrier Repair Cream;Null Formula 8-in-1 BioSerum
41 Split-face Study of Changing in Skin Physiology and Clinical Appearance After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces Completed NCT02312154 Phase 4
42 Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART Completed NCT01869634 Phase 4 darunavir with ritonavir and fixed-dose viread+emtricitabine daily
43 Efficacy and Safety of a Mixed Extract of Fenugreek Seed and Lespedeza Cuneata in the Treatment of Testosterone Deficiency Syndrome: A Randomized, Double-blind, Placebo-Controlled Clinical Trial Completed NCT03057899 Phase 4 TFG capsules (200 mg /capsule);Placebo oral capsule
44 3% Dihydroxyacetone (DHA or Sunless Tanning Agent) Inhibits Vitamin D Production in the Skin in Response to Ultraviolet Light Completed NCT00818467 Phase 4
45 Oral Administration of L-Arginine in Patients With Erectile Dysfunction Completed NCT00777075 Phase 4 L-arginine;Placebo
46 Randomized, Controlled, Multi-Centered, Double-Blind Investigation of Injectable Poly-L-Lactic Acid (Sculptra Aesthetic) for Improving Facial Wrinkles and Skin Quality Completed NCT02003833 Phase 4
47 Preventing Delirium in Hospitalized Elderly Completed NCT00182884 Phase 4 Donepezil
48 Memory and Mental Health in Aging: Psychopharmacological Augmentation of Memory Training in Older Adults Completed NCT02988908 Phase 4 Donepezil;Placebos
49 A 1-year Randomised, Double-blind Placebo-controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients With Alzheimer's Disease Completed NCT00862940 Phase 4 Memantine;Placebo
50 Comparison of Clinical Outcome Parameters, the Patient Benefit Index (PBI) and Patient Satisfaction After Ablative Fractional Laser Treatment of Peri-orbital Rhytides Completed NCT00994474 Phase 4

Search NIH Clinical Center for Aging

Genetic Tests for Aging

Anatomical Context for Aging

MalaCards organs/tissues related to Aging:

40
Brain, Skin, Heart, Bone, Kidney, Breast, Skeletal Muscle

Publications for Aging

Articles related to Aging:

(show top 50) (show all 30015)
# Title Authors PMID Year
1
Lamin A-dependent nuclear defects in human aging. 61 56
16645051 2006
2
Genome dynamics in aging mice. 61 56
12421760 2002
3
Mitochondrial genetics: a paradigm for aging and degenerative diseases? 61 56
1533953 1992
4
Short telomeres are sufficient to cause the degenerative defects associated with aging. 56
19944403 2009
5
Increased cell-to-cell variation in gene expression in ageing mouse heart. 56
16791200 2006
6
Gene regulation and DNA damage in the ageing human brain. 56
15190254 2004
7
Strikingly higher frequency in centenarians and twins of mtDNA mutation causing remodeling of replication origin in leukocytes. 56
12538859 2003
8
Mitochondrial DNA polymorphisms associated with longevity in a Finnish population. 56
12483296 2003
9
Muscle-specific mutations accumulate with aging in critical human mtDNA control sites for replication. 56
11274426 2001
10
Distinct spectra of somatic mutations accumulated with age in mouse heart and small intestine. 56
10900004 2000
11
Role of nuclear background and in vivo environment in variable segregation behavior of the aging-dependent T414G mutation at critical control site for human fibroblast mtDNA replication. 56
15328912 1999
12
Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. 56
10531063 1999
13
Mitochondrial genotype associated with longevity. 56
9449878 1998
14
Growing old: the most common mitochondrial disease of all? 56
1303273 1992
15
Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. 56
1303287 1992
16
Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. 56
1303288 1992
17
Accumulation of deletions in human mitochondrial DNA during normal aging: analysis by quantitative PCR. 56
1463763 1992
18
Evidence for and against the causal involvement of mitochondrial DNA mutation in mammalian ageing. 56
1383763 1992
19
Strength and aging resistance of monolithic zirconia: an update to current knowledge. 61
31768195 2020
20
Fingolimod (FTY720) improves postoperative cognitive dysfunction in mice subjected to D-galactose-induced aging. 61
31960817 2020
21
Combined effects of gamma irradiation and aging on tenderness and quality of beef from Nellore cattle. 61
31927210 2020
22
Activation of group 2 innate lymphoid cells alleviates aging-associated cognitive decline. 61
32022838 2020
23
Inflammatory markers associated with fall recurrence and severity: The Bambuí Cohort Study of Aging. 61
31935439 2020
24
Vitamin D, menopause, and aging: quo vadis? 61
31736391 2020
25
Accelerated extrinsic epigenetic aging and increased natural killer cells in blood of suicide completers. 61
31707091 2020
26
Lesbian, Gay, Bisexual, and Transgender Persons Aging in Rural Areas. 61
30862175 2020
27
Strategies for Promoting Successful Aging and Well-Being. 61
32019436 2020
28
Veganism, aging and longevity: new insight into old concepts. 61
31895244 2020
29
Editorial: Forging new frontiers in HIV and aging. 61
32000248 2020
30
HIV, aging, and adherence: an update and future directions. 61
31977338 2020
31
Octogenarians with Multiple Sclerosis: Lessons for Aging in Place. 61
31084628 2020
32
Inflammaging is associated with shifted macrophage ontogeny and polarization in the aging mouse ovary. 61
31940276 2020
33
A Self-Reliant Umbrella: Defining Successful Aging Among the Old-Old (80+) in Shanghai. 61
30943800 2020
34
Dynamics of human monocytes and airway macrophages during healthy aging and after transplant. 61
31917836 2020
35
Affective theory of mind in human aging: is there any relation with executive functioning? 61
30994403 2020
36
Lonely SARTs: loneliness and sustained attention in the Irish longitudinal study of aging. 61
30999806 2020
37
Current nutritional and pharmacological anti-aging interventions. 61
31816437 2020
38
Sex Differences in People Aging With HIV. 61
32032279 2020
39
Impaired Neovascularization in Aging. 61
31993253 2020
40
Senotherapeutics for HIV and aging. 61
31833962 2020
41
Communicative Predictors of Older Adults' Successful Aging, Mental Health, and Alcohol Use. 61
29983078 2020
42
Three-dimensional evaluation of important surgical landmarks of the face during aging. 61
31678402 2020
43
Autophagy in Female Fertility: A Role in Oxidative Stress and Aging. 61
31892284 2020
44
What is the collective effect of aging and HIV on the gut microbiome? 61
31876548 2020
45
Skin Structure-Function Relationships and the Wound Healing Response to Intrinsic Aging. 61
31993254 2020
46
Monitoring plasma protein aggregation during aging using conformation-specific antibodies and FTIR spectroscopy. 61
31790700 2020
47
Aging membranes: Unexplored functions for lipids in the lifespan of the central nervous system. 61
31862420 2020
48
The intersection of exercise and aging on mitochondrial protein quality control. 61
31911185 2020
49
Microbial aging of hydrochar as a way to increase cadmium ion adsorption capacity: Process and mechanism. 61
31926474 2020
50
Excision of endosymbiotic bacteria from yeast under aging and starvation stresses. 61
31839588 2020

Variations for Aging

Expression for Aging

Search GEO for disease gene expression data for Aging.

Pathways for Aging

Pathways related to Aging according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.6 TP53 SOD2 SOD1 SNCA PPARG MAPK1
2
Show member pathways
13.18 TP53 SOD2 SOD1 SIRT1 MAPK1 JUN
3
Show member pathways
12.88 TP53 PPARG PDGFRB MAPK1 JUN AKT1
4 12.84 TP53 PPARG PDGFRB MAPK1 JUN AKT1
5
Show member pathways
12.81 TP63 TP53 MAPK1 LMNA JUN AKT1
6 12.8 TP53 PDGFRB MAPK1 JUN AKT1
7
Show member pathways
12.76 TP53 PDGFRB MAPK1 KL AKT1
8
Show member pathways
12.71 TP53 PDGFRB MAPK1 JUN AKT1
9
Show member pathways
12.65 TP53 PDGFRB MAPK1 JUN AKT1
10 12.56 TP63 TP53 SIRT1 PDGFRB MAPK1
11
Show member pathways
12.54 TP53 MAPK1 JUN AKT1
12
Show member pathways
12.48 TP53 PDGFRB JUN AKT1
13
Show member pathways
12.46 TP53 SIRT3 SIRT1 PDGFRB MAPK1 JUN
14
Show member pathways
12.44 PDGFRB MAPK1 JUN AKT1
15 12.44 SOD2 SIRT3 SIRT1 PPARG NAMPT AKT1
16
Show member pathways
12.43 TP53 SIRT1 PPARG MAPK1 AKT1
17 12.41 TP53 MAPK1 JUN AKT1
18 12.37 TP53 MAPK1 JUN AKT1
19
Show member pathways
12.36 TP53 SOD2 SOD1 SERPINE1
20
Show member pathways
12.35 TP53 MAPK1 JUN AKT1
21
Show member pathways
12.35 PPARG PDGFRB MAPK1 AKT1
22
Show member pathways
12.23 TP53 PDGFRB MAPK1 LMNA AKT1
23
Show member pathways
12.23 TP53 SIRT3 SIRT1 MAPK1 AKT1
24
Show member pathways
12.2 TP53 PPARG JUN AKT1
25
Show member pathways
12.17 TP53 MAPK1 JUN AKT1
26
Show member pathways
12.16 PDGFRB MAPK1 JUN AKT1
28
Show member pathways
12.11 SOD2 SIRT1 MAPK1 AKT1
29 12.11 TP53 SIRT1 SERPINE1 MAPK1 AKT1
30 12.09 TP53 MAPK1 JUN AKT1
31
Show member pathways
12.08 TP53 MAPK1 JUN AKT1
32 12.08 TP63 TP53 SERPINE1 JUN
33 12.08 SERPINE1 PPARG NAMPT LMNA
34 12.08 TP53 SIRT1 MAPK1 JUN AKT1
35 12.06 PPARG MAPK1 JUN AKT1
36
Show member pathways
12 PDGFRB MAPK1 JUN AKT1
37 11.97 TP53 PDGFRB MAPK1 AKT1
38 11.94 TP53 SERPINE1 MAPK1 JUN
39 11.91 SERPINE1 MAPK1 JUN AKT1
40 11.89 TP53 SOD2 MAPK1 JUN AKT1
41
Show member pathways
11.89 TP53 SERPINE1 PPARG MAPK1 JUN AKT1
42 11.87 PPARG MAPK1 JUN AKT1
43
Show member pathways
11.86 MAPK1 JUN AKT1
44 11.85 TP63 TP53 AKT1
45
Show member pathways
11.83 MAPK1 JUN AKT1
46 11.8 SERPINE1 JUN AKT1
47
Show member pathways
11.8 PDGFRB MAPK1 JUN AKT1
48 11.78 TP53 MAPK1 JUN AKT1
49 11.77 SIRT1 PPARG AKT1
50 11.77 TP53 MAPK1 AKT1

GO Terms for Aging

Cellular components related to Aging according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 10.06 WRN TP63 TP53 SOD1 SIRT3 SIRT1
2 nucleus GO:0005634 10.03 WRN TP63 TP53 SOD1 SNCA SIRT3
3 mitochondrial matrix GO:0005759 9.65 TP53 SOD2 SOD1 SNCA SIRT3
4 mitochondrion GO:0005739 9.61 TP63 TP53 SOD2 SOD1 SNCA SIRT3
5 protein-containing complex GO:0032991 9.23 TP63 TP53 SOD1 SNCA SIRT3 PPARG

Biological processes related to Aging according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10.18 TP63 TP53 SNCA SIRT1 PPARG JUN
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.15 TP63 TP53 SIRT1 SERPINE1 PPARG NAMPT
3 apoptotic process GO:0006915 10.14 TP63 TP53 SNCA SIRT1 MAPK1 AKT1
4 positive regulation of transcription, DNA-templated GO:0045893 10.12 TP63 TP53 PPARG MAPK1 JUN AKT1
5 cellular response to DNA damage stimulus GO:0006974 10.1 WRN TP53 SIRT1 MAPK1 AKT1
6 positive regulation of cell proliferation GO:0008284 10.09 SIRT1 PDGFRB NAMPT MAPK1 JUN AKT1
7 negative regulation of cell proliferation GO:0008285 10.08 TP53 SOD2 PPARG LMNA JUN
8 response to drug GO:0042493 10.03 TP53 SOD1 SNCA PPARG JUN
9 regulation of apoptotic process GO:0042981 9.97 WRN TP63 TP53 SIRT1 AKT1
10 negative regulation of neuron apoptotic process GO:0043524 9.94 SOD2 SOD1 SNCA JUN
11 rhythmic process GO:0048511 9.93 TP53 SIRT1 PPARG NAMPT
12 regulation of signal transduction by p53 class mediator GO:1901796 9.92 WRN TP63 TP53 AKT1
13 cellular response to hypoxia GO:0071456 9.92 TP53 SIRT1 LMNA AKT1
14 insulin receptor signaling pathway GO:0008286 9.89 NAMPT KL AKT1
15 protein homotetramerization GO:0051289 9.88 TP63 TP53 SOD2
16 protein import into nucleus GO:0006606 9.88 TP53 LMNA AKT1
17 response to organic cyclic compound GO:0014070 9.88 PPARG PDGFRB NAMPT JUN
18 positive regulation of endothelial cell proliferation GO:0001938 9.86 SIRT1 JUN AKT1
19 negative regulation of apoptotic process GO:0043066 9.86 TP53 SOD1 SNCA SIRT1 RGN PDGFRB
20 regulation of blood pressure GO:0008217 9.85 SOD2 SOD1 PPARG
21 negative regulation of neuron death GO:1901215 9.85 SNCA SIRT1 AKT1
22 response to estrogen GO:0043627 9.84 PPARG PDGFRB MAPK1
23 response to retinoic acid GO:0032526 9.83 TP53 PPARG PDGFRB
24 response to organic substance GO:0010033 9.83 SOD1 PPARG JUN AKT1
25 response to oxidative stress GO:0006979 9.83 WRN TP53 SOD1 SIRT1 AKT1
26 cellular response to ionizing radiation GO:0071479 9.78 TP53 SIRT1 NAMPT
27 positive regulation of smooth muscle cell proliferation GO:0048661 9.78 PDGFRB NAMPT JUN AKT1
28 protein tetramerization GO:0051262 9.77 TP63 TP53 SNCA
29 response to hydrogen peroxide GO:0042542 9.76 SOD1 SIRT1 PDGFRB JUN
30 positive regulation of apoptotic process GO:0043065 9.76 TP53 SOD1 SNCA SIRT1 PPARG PDGFRB
31 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.74 TP63 TP53 SIRT1
32 microglial cell activation GO:0001774 9.73 SNCA NAMPT JUN
33 circadian rhythm GO:0007623 9.72 TP53 SIRT1 SERPINE1 NAMPT JUN
34 positive regulation of vascular associated smooth muscle cell apoptotic process GO:1905461 9.71 SOD2 PPARG
35 protein deacetylation GO:0006476 9.71 SIRT3 SIRT1
36 cellular response to reactive oxygen species GO:0034614 9.71 TP53 MAPK1 JUN AKT1
37 negative regulation of telomerase activity GO:0051974 9.7 TP53 PPARG
38 response to caffeine GO:0031000 9.7 TP53 PPARG
39 positive regulation of glucose metabolic process GO:0010907 9.69 RGN AKT1
40 DNA synthesis involved in DNA repair GO:0000731 9.69 WRN SIRT1
41 release of cytochrome c from mitochondria GO:0001836 9.69 TP53 SOD2 JUN
42 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.68 MAPK1 AKT1
43 response to fluid shear stress GO:0034405 9.68 PDGFRB AKT1
44 peptidyl-lysine deacetylation GO:0034983 9.68 SIRT3 SIRT1
45 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.67 SOD2 SIRT1 AKT1
46 cellular response to cadmium ion GO:0071276 9.67 SOD1 MAPK1 JUN AKT1
47 peripheral nervous system myelin maintenance GO:0032287 9.66 SOD1 AKT1
48 replicative cell aging GO:0001302 9.65 WRN TP63
49 response to superoxide GO:0000303 9.65 SOD2 SOD1
50 negative regulation of helicase activity GO:0051097 9.59 TP53 SIRT1

Molecular functions related to Aging according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 10.01 WRN TP53 SOD1 NAMPT JUN AKT1
2 zinc ion binding GO:0008270 10 TP53 SOD1 SNCA SIRT3 RGN PPARG
3 chromatin binding GO:0003682 9.88 WRN TP63 TP53 PPARG JUN
4 transcription factor binding GO:0008134 9.8 TP53 SIRT1 PPARG MAPK1 JUN
5 identical protein binding GO:0042802 9.7 TP63 TP53 SOD2 SOD1 SNCA SIRT1
6 p53 binding GO:0002039 9.69 TP63 TP53 SIRT1
7 copper ion binding GO:0005507 9.63 TP53 SOD1 SNCA
8 double-stranded DNA binding GO:0003690 9.56 TP63 PPARG MAPK1 JUN
9 transcription regulatory region DNA binding GO:0044212 9.55 TP63 TP53 SNCA PPARG JUN
10 MDM2/MDM4 family protein binding GO:0097371 9.49 TP63 TP53
11 NAD-dependent protein deacetylase activity GO:0034979 9.43 SIRT3 SIRT1
12 superoxide dismutase activity GO:0004784 9.37 SOD2 SOD1
13 NAD-dependent histone deacetylase activity GO:0017136 9.32 SIRT3 SIRT1
14 enzyme binding GO:0019899 9.28 TP53 SOD1 SNCA SIRT3 SIRT1 PPARG

Sources for Aging

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO